Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sqz Biotechnologies Company (NY: SQZ ) N/A UNCHANGED Last Price Updated: 5:00 PM EDT, Jul 3, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sqz Biotechnologies Company < Previous 1 2 3 Next > Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider May 06, 2024 From GENENTA SCIENCE SPA Via GlobeNewswire SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split June 15, 2023 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates May 10, 2023 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial March 22, 2023 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates March 22, 2023 From SQZ Biotechnologies Company Via Business Wire NYSE:SQZ Investor Alert: Investigation over Potential Wrongdoing at SQZ Biotechnologies Company February 27, 2023 San Diego, CA -- (SBWIRE) -- 02/27/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company. Via SBWire SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange January 18, 2023 From SQZ Biotechnologies Via Business Wire NYSE:SQZ Investor Notice: Investigation over Possible Securities Laws Violations by SQZ Biotechnologies Company December 13, 2022 San Diego, CA -- (SBWIRE) -- 12/13/2022 -- SQZ Biotechnologies Company is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress December 06, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer November 30, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting November 10, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates November 09, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy October 03, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies September 12, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies to Present at Upcoming Investor Conferences September 07, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Announces Leadership Transition September 06, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates August 04, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation July 12, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer July 11, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs June 16, 2022 From SQZ Biotechnologies Company Via Business Wire SQZ Biotechnologies to Present at Jefferies Healthcare Conference June 01, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer May 31, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process May 18, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates May 10, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022 May 05, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research May 05, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies to Present at Upcoming Investor Conferences May 03, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 27, 2022 From SQZ Biotechnologies Via Business Wire SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022 From SQZ Biotechnologies Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
